Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2005 1
2006 3
2007 6
2008 1
2009 3
2010 1
2011 3
2012 2
2014 6
2015 4
2016 4
2017 3
2019 7
2020 12
2021 8
2022 10
2023 9
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

80 results

Results by year

Filters applied: . Clear all
Page 1
Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice.
Suárez-García I, Alejos B, Hernando V, Viñuela L, Vera García M, Rial-Crestelo D, Pérez Elías MJ, Albendín Iglesias H, Peraire J, Tiraboschi J, Díaz A, Moreno S, Jarrín I; Cohort of the Spanish HIV/AIDS Research Network (CoRIS). Suárez-García I, et al. J Antimicrob Chemother. 2023 Jun 1;78(6):1423-1432. doi: 10.1093/jac/dkad102. J Antimicrob Chemother. 2023. PMID: 37099559 Free PMC article.
Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir.
González-Cordón A, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Stellbrink HJ, Guaraldi G, Masiá M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Behrens G, Pozniak A, Gatell JM, Martínez E; NEAT 022 Study Group. González-Cordón A, et al. J Antimicrob Chemother. 2023 Sep 5;78(9):2361-2365. doi: 10.1093/jac/dkad247. J Antimicrob Chemother. 2023. PMID: 37539492
Extracutaneous atypical syphilis in HIV-infected patients.
Prieto P, Imaz A, Calatayud L, García O, Saumoy M, Podzamczer D. Prieto P, et al. Among authors: saumoy m. Med Clin (Barc). 2017 Dec 7;149(11):488-492. doi: 10.1016/j.medcli.2017.06.006. Epub 2017 Jul 22. Med Clin (Barc). 2017. PMID: 28739269 English, Spanish.
Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial.
Waters L, Assoumou L, González-Cordón A, Rusconi S, Domingo P, Gompels M, de Wit S, Raffi F, Stephan C, Masiá M, Rockstroh J, Katlama C, Behrens GMN, Moyle G, Johnson M, Fox J, Stellbrink HJ, Guaraldi G, Florence E, Esser S, Gatell JM, Pozniak A, Martínez E; NEAT 022 Study Group. Waters L, et al. Clin Infect Dis. 2023 Mar 4;76(5):861-870. doi: 10.1093/cid/ciac827. Clin Infect Dis. 2023. PMID: 36259527 Clinical Trial.
Total and Unbound Doravirine Concentrations and Viral Suppression in CSF.
Tiraboschi J, Scévola S, Penchala SD, Challenger E, Else L, Prieto P, Saumoy M, Imaz A, Silva-Klug A, Niubó J, Soriano I, Khoo S, Rigo-Bonin R, Podzamczer D. Tiraboschi J, et al. Among authors: saumoy m. Clin Infect Dis. 2022 May 30;74(10):1855-1858. doi: 10.1093/cid/ciab835. Clin Infect Dis. 2022. PMID: 34549268
Cardiovascular events in delayed presentation of HIV: the prospective PISCIS cohort study.
Martín-Iguacel R, Vazquez-Friol MC, Burgos J, Bruguera A, Reyes-Urueña J, Moreno-Fornés S, Aceitón J, Díaz Y, Domingo P, Saumoy M, Knobel H, Dalmau D, Borjabad B, Johansen IS, Miro JM, Casabona J, Llibre JM. Martín-Iguacel R, et al. Among authors: saumoy m. Front Med (Lausanne). 2023 Jun 21;10:1182359. doi: 10.3389/fmed.2023.1182359. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37415770 Free PMC article.
80 results